Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 83, Issue 3, 2014, Pages 363-368

  Reinmuth, N ^a   Meyer, A ^b   Hartwigsen, D ^c   Schaeper, C ^d   Huebner, G ^e   Skock Lober, R ^f   Bier, A ^g   Gerecke, U ^h   Held, C P ⁱ   Reck, M ^a  

^a Member of the German Center for Lung Research   (Germany)

^b Kliniken Maria Hilf   (Germany)

^c Krankenhaus St Franziskus   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e SANA KLINIKUM OFFENBACH   (Germany)

^f HELIOS KLINIKEN SCHWERIN   (Germany)

^g Pneumology   (Germany)

^h Hanse Klinikum   (Germany)

ⁱ Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH   (Germany)

Author keywords

Chemotherapy; Cisplatin; First line therapy; Nitroglycerin; Non small cell lung cancer; Oral vinorelbine

Indexed keywords

CHEMOTHERAPY; CISPLATIN; FIRST-LINE THERAPY; NITROGLYCERIN; NON-SMALL CELL LUNG CANCER; ORAL VINORELBINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROGLYCERIN; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 84894281964     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.001     Document Type: Article

References (36)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer, Lyon, France.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2013, 63:11-30.
3. Travis W., Travis L., Devesa S. Lung cancer. Cancer 1995, 75:191-202.
4. Goeckenjan G., Sitter H., Thomas M., Branscheid D., Flentje M., Griesinger F., et al. Prevention, diagnosis, therapy and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and German Cancer Society. Pneumologie 2010, 64(Suppl. 2):e1-e164.
5. D'Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
6. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27(36):6251-6266.
7. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. 2011 focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29(28):3825-3831.
8. Depierre A., Chastang C., Quoix E., Lebeau B., Blanchon F., Paillot N., et al. Vinorelbine vs. vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994, 5:37-42.
9. Le Chevalier T., Brisgand D., Douillard J.-Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12:360-367.
10. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a southwest oncology group study. J Clin Oncol 1998, 16:2459-2465.
11. Le Chevalier T., Brisgand D., Soria J.C., Douillard J.Y., Pujol J.L., Ruffie P., et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001, 6(1):8-11.
12. Gridelli C. The ELVIS-trial: a phase III study of single agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Oncologist 2001, 6(1):4-7.
13. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
14. Martoni A., Marino A., Sperandi F., Giaquinta S., Di Fabio F., Melotti B., et al. Multicentre randomized phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small-cell lung cancer. Eur J Cancer 2005, 41:81-92.
15. Helbekkmo N., Sundstrom S.H., Aasebo U., Brunsvig P.F., von Plessen C., Hjelde H.H., et al. Vinorelbine/carboplatin vs gemcitabine carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007, 97(3):283-289.
16. Gebbia V., Galetta D., Lorusso V., Caruso M., Verderame F., Pezzella G., et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (gruppo oncologico Italia meridionale). Lung Cancer 2008, 61:369-377.
17. Tan E.H., Rolski J., Grodzki T., Schneider C.P., Gatzemeier U., Zatloukal P., et al. Global lung oncology branch trial 3 (GLOB 3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009, 20:1249-1256.
18. Flotten O., Gronberg B.H., Bremnes R., Amundsen T., Sundstrom S., Rolke H., et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomized controlled trial by the Norwegian lung cancer study group. Br J Cancer 2012, 107:442-447.
19. Principles and practice of oncology 1997, Lipcott-Raven. V.T. Vita, S. Hellman, S.A. Rosenberg (Eds.).
20. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001, 12:1643-1649.
21. Bourgeois H., Vermorken J., Dark G., Jones A., Fumoleau P., Stupp R., et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumors. Cancer Chemother Pharmacol 2007, 60:407-413.
22. Variol P., Nguyen L., Tranchaud B., Puozzo C. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 2002, 58:467-476.
23. Jassem J., Ramlau R., Karnicka-Młodkowska H., Krawczyk K., Krzakowski M., Zatloukal P., et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001, 12:1375-1381.
24. Jassem J., Ramlau R., Karnicka-Mlodkowska H., Krawczyk K., Krzakowski M., Zatloukal P., et al. Corrigendum: A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients [Ann Oncol 2001;12:1375-81]. Ann Oncol 2002, 13:493.
25. Zhang L., Jianhua C., Huang C., Wang J., Yongqian S., Zhang Y., et al. Open-label, randomised multicentre, phase II trial of Oral vinorelbine (NVBo) or intravenous vinorelbine (NVBiv) with cisplatin (CDDP) in patients (pts) with advanced Non Small Cell Lung Cancer (NSCLC): a Chinese experience. WCLC 2011, P3015.
26. De Lena M., Ramlau R., Hansen O., Lorusso V., Wagner L., Barni S., et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 2005, 48:129-135.
27. Jensen L.H., Osterlind K., Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008, 62:85-91.
28. Yasuda H., Yamaya M., Nakayama K., Sasaki T., Ebihara S., Kanda A., et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006, 24:688-694.
29. Jordan B.F., Misson P., Demeure R., Baudelet C., Beghein N., Gallez B. Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000, 48:565-570.
30. Xie K., Huang S., Dong Z., Juang S.H., Wang Y., Fidler I.J. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997, 89:421-427.
31. Vamvakas S., Schmidt H.H. Just say NO to cancer. J Natl Cancer Inst 1997, 89:406-407.
32. Jarry A., Charrier L., Bou-Hanna C., Devilder M.C., Crussaire V., Denis M.G., et al. Position in cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death. Cancer Res 2004, 64:4227-4234.
33. Thomas D.D., Espey M.G., Ridnour L.A., Hofseth L.J., Mancardi D., Harris C.C., et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004, 101:8894-8899.
34. Cook T., Wang Z., Alber S., Liu K., Watkins S.C., Vodovotz Y., et al. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 2004, 64:8015-8021.
35. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
36. Han J.Y., Nam B.H., Kim H.Y., Yoon S.J., Kim H.T., Lee J.S. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer. Ann Oncol 2012, 23(11):2925-2930.